Last Updated: September 11, 2026
340B alternatives are the third-party administration models, platforms, and internal operating structures covered entities use to run the drug discount program without carrying the full compliance load themselves. This guide from The Marketing Lab covers what each model actually does, what it costs you in control, and how to choose.
The pressure is real. HRSA tightened documentation standards for covered entities whose eligibility rests on in-kind support, and manufacturer restrictions on contract pharmacy claims keep multiplying. Most FQHCs did not staff up for either.
Below, we break down the four administrator models, a reconciliation habit that catches most statement errors, and a 10-question checklist to run before signing anything.
340B administrator models differ less on the software they show you and more on who owns the compliance work when HRSA asks a question. That ownership question is what separates a full-service performance-aligned TPA from a tool, a distributor bundle, or an advisory retainer.
Full-service performance-aligned TPAs own the operational work: eligibility files, recertification documentation, prescriber rosters, contract pharmacy setup and transitions, manufacturer-restriction tracking, and audit defense. RxLeverage runs on this model with zero base fees and performance-aligned pricing, which means the administrator earns when the entity earns.
Software-only platforms sell split-billing and inventory tools. The clinic still owns every compliance obligation, including the recertification file and the roster reconciliation.
Distributor-run programs bundle 340B administration with wholesale supply chain. Strong logistics, less flexibility for smaller independent clinics that need custom carve-out logic.
Consulting-only firms advise on strategy and program integrity but do not execute day-to-day operations, so the clinic still staffs the work.
| Model | Who Owns Recert Files | Prescriber Roster Reconciliation | Contract Pharmacy Transition and Cash-Flow Modeling | Statement Transparency | Manufacturer-Restriction Tracking | Audit Support | Termination Terms |
|---|---|---|---|---|---|---|---|
| Full-service TPA (RxLeverage) | Administrator | Quarterly against EHR rendering NPI | Modeled month by month, cash and accrual | Cash and accrual views | By drug and NDC | Included | Defined notice, post-termination audit rights |
| Software-only | Clinic | Clinic | No | Depends on clinic reporting | Depends on module | Limited | Platform contract terms |
| Distributor-run | Shared | Shared | Supply-chain tied | Subscription reporting | Partial | Yes | Distributor contract terms |
| Consulting-only | Clinic | Advisory only | Advisory only | None | Advisory only | Project-based | Engagement letter |
340B contract pharmacy reconciliation is the monthly process of matching what the pharmacy collected, what the clinic is owed, and what remains in trailing insurer A/R. Skipping it is how margin quietly disappears.
A cash-basis "cumulative over/under" ledger can show the clinic owing the pharmacy while the accrual view shows the pharmacy holding clinic margin in trailing insurer A/R. In programs we run, roughly 30% of that A/R collects in-month and about 70% the following month (hrsa.gov).
"Cash start-up" advances at a fixed percentage of charges create a liability that only flips once A/R collects. Model the transition month by month before signing.
HRSA 340B audit readiness means the entity can produce a complete, internally consistent documentation package within days of a records request, not weeks. The failures we see are rarely missing binders; they are mismatches between what the entity attested to and what the underlying records show.
In-kind eligibility documentation. Section 318 STD entities whose eligibility rests on in-kind support, such as HIV test kits from a state health department, must hold the grantee's Notice of Award and an executed subrecipient agreement showing recipient and subrecipient names and addresses, grant number, NOFO number, terms of support, and a funding date range. Single-date in-kind entries and unsigned drafts are the common gaps. HRSA tightened this in its August 2025 and January 2026 information-collection notices, and ineligibility means removal from the program and manufacturer repayment.
Prescriber roster drift. TPA prescriber configs drift between reviews. In one audit we worked, roughly a third of active rendering providers were missing, including the owner, because mid-levels rendered under a supervising NPI or the EHR carried the wrong NPI. Reconcile the TPA config against an EHR claims report by rendering NPI every quarter, and list supervised providers under both NPIs.
Medicaid Exclusion File alignment. The entity's Medicaid ID must appear on the HRSA Medicaid Exclusion File. FFS pharmacy claims carry Basis of Cost 08 and Submission Clarification Code 20, ingredient cost is capped at the 340B ceiling price plus the state dispensing fee, and managed care encounters use SCC 20 and 9 per plan spec. A mismatch here is a duplicate discount finding waiting to happen.
Automation covers eligibility verification, inventory tracking, split-billing reconciliation, prescriber roster drift detection, and manufacturer restriction monitoring.
It does not cover clinical judgment, the entity's own attestation, or the decision about which drugs to carve out. Those stay with the covered entity.
HRSA Office of Pharmacy Affairs 340B program guidance publishes the eligibility and recertification standards that any administrator must build against.
Exiting 340B is rarely the right answer, but it deserves an honest look when administrative burden outpaces savings.
Reasons entities consider exit: persistent negative net-per-claim on high-volume generics, audit exposure the entity cannot staff against, and contract pharmacy relationships that consume more margin than they return.
What exit costs: loss of drug discount savings that fund medication access and patient assistance programs, and reduced financial sustainability for safety net providers serving uninsured patients.
340B Health program resources tracks the regulatory developments that shape this decision.
Middle path: carve out unprofitable drug classes, renegotiate pharmacy agreements, or move to a performance-aligned TPA before considering full exit.
Choosing a 340B alternative comes down to who owns the compliance work and whether you can read the money. Full-service models like RxLeverage take recertification files, prescriber roster audits, contract pharmacy transitions, and HRSA audit readiness off the clinic's plate, with performance-aligned pricing and no base fees. Pair that with VaultStream for HIPAA-compliant patient journeys and reporting wired to kept appointments, not clicks. Book a free 30-minute strategy call at https://thelab.marketing/schedule and get a straight read on your program.
Software-only platforms give you a dashboard and leave eligibility files, prescriber rosters, contract pharmacy setup and audit defense to your staff. Full-service administrators like RxLeverage own those tasks end to end. The practical split shows up in two places: who is named as responsible when HRSA requests documentation, and who reconciles your TPA prescriber config against the EHR every quarter. Clinics with one part-time 340B manager usually need the full-service model; groups with a dedicated compliance team can run software-only.
Ask for one month of statements in both cash and accrual views before signing anything. In our experience, a cash-basis cumulative ledger can show the clinic owing the pharmacy while the accrual view shows the pharmacy holding clinic margin in trailing insurer A/R, often with roughly 30% collected in-month and 70% the following month. Also ask whether any start-up advance is repaid from future claims, and request a true-up of the withhold reserve in writing.
It is often the first thing an auditor tests. TPA prescriber configurations drift: mid-levels render under a supervising NPI, or the EHR carries a different NPI than the one on file. In one audit we worked through, roughly a third of active rendering providers were missing from the config, including the owner. Reconcile the TPA config against an EHR claims report by rendering NPI every quarter, and list supervised providers under both NPIs.
Distributor-run programs tend to surface restrictions through their own supply chain reporting. Boutique and full-service administrators usually track restrictions at the drug and NDC level and flag claims that fall outside a manufacturer's contract pharmacy policy. What matters operationally is whether the restriction list is refreshed on a defined schedule and whether someone owns the carve-out decision when a drug class turns negative. Ask for a sample restriction report before you commit.
Most pharmacy services agreements we review include 60-day no-cause termination, no exclusivity clause because patient choice governs, quarterly reconciliation, a withhold reserve releasable on request, two-year post-termination audit rights, and payment terms that step from 90 days to 30 days over the first months. If you plan to change pharmacies, reduce volume first, let A/R collect, request the reserve true-up, then give notice. Model the transition month by month before you sign.
Bring us your patient acquisition, 340B program, or compliance bottleneck. We will show you what a 30-day launch looks like for your clinic — in English or Spanish, month to month, no long contract.
